Immutep (ASX:IMM)
Source: Immutep
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep (IMM) signs a manufacturing service agreement with Northway Biotech to manufacture its preclinical candidate for autoimmune diseases ahead of clinical testing
  • Northway has already begun developing a manufacturing process for the drug and will produce it in large scale bioreactors
  • After completion of the required preclinical development, the material produced will be used for Immutep’s clinical trials of IMP761
  • The company says it’s working towards further pre-clinical and clinical development of its drug candidate
  • Immutep last traded at 47 cents at 12:00pm AEDT f

Immutep (IMM) has signed a manufacturing service agreement with Northway Biotech to manufacture IMP761 ahead of clinical testing.

Northway Biotech is a European end-to-end biopharmaceutical contract development and manufacturing organisation that will manufacture IMP761, Immutep’s preclinical candidate for autoimmune diseases.

As a targeted immunosuppressive antibody, IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing the autoimmune memory T cells accumulating at the disease site which express LAG-3 as an exhaustion marker after being repeatedly stimulated with dominant self-peptides at the disease site.

Under the agreement, Northway has already started developing a GMP-compliant manufacturing process of IMP761 and will manufacture the drug in large scale bioreactors. The work will be undertaken at Northway’s Lithuanian facility, with the potential to expand the agreement to include further process scale-up and cover commercial supply in the future.

CEO of Immutep, Marc Voigt said the company is very excited to be partnering with Northway Biotech to develop a GMP manufacturing process for IMP76.

“As a targeted immunosuppressive antibody, IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing the autoimmune memory T cells accumulating at the disease site, known to express LAG-3. We are very pleased to be moving IMP761 towards clinical trials,” Mr Voigt said.

After completion of the required preclinical development, the material produced will be used for Immutep’s clinical trials of IMP761.

The company says it’s working towards further pre-clinical and clinical development of its drug candidate.

Immutep last traded at 47 cents at 12:00pm AEDT.

IMM by the numbers
More From The Market Herald

" Live Verdure (ASX:LV1) partners with TruLife for US distribution

Food, skincare and nutraceutical company Live Verdure (ASX:LV1) has entered a non-executive national sales and distribution…
SECOS Group (ASX:SES) - CEO, Ian Stacey

" SECOS (ASX:SES) launches MyEcoBag and MyEcoPet through Pacchini

Sustainable packaging company, SECOS (ASX:SES) has launched MyEcoBag and MyEcoPet through Pacchini Sales and Distribution to…

" Solis Minerals (ASX:SLM) kicks off drilling at Mostazal copper project

Newly listed Solis Minerals (ASX:SLM) has hit the ground at its Mostazal copper project in Chile…
Argenica Therapeutics (ASX:AGN) - CEO, Dr Liz Dallimore

" Argenica Therapeutics (ASX:AGN) determines safe starting dose level for ARG-007

Argenica Therapeutics (ASX:AGN) determines safe starting dose level from toxicology and genotoxicity studies